[
  {
    "ts": null,
    "headline": "Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say",
    "summary": "Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
    "url": "https://finnhub.io/api/news?id=6bd278dec38bd339fef78358019829e7cdd51cbef0254de228d5b60cd49b47b8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745535604,
      "headline": "Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say",
      "id": 134067677,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
      "url": "https://finnhub.io/api/news?id=6bd278dec38bd339fef78358019829e7cdd51cbef0254de228d5b60cd49b47b8"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.",
    "summary": "Executives told Barron’s that the company is well-positioned to handle potential pharmaceutical tariffs.",
    "url": "https://finnhub.io/api/news?id=e306a090478a8e3232b5a80831094927d10bbcbdd76c7bf415dbb9fb4bc6aec3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745531580,
      "headline": "Gilead Sciences Earnings Were Solid. Why the Stock Is Dropping.",
      "id": 134067678,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Executives told Barron’s that the company is well-positioned to handle potential pharmaceutical tariffs.",
      "url": "https://finnhub.io/api/news?id=e306a090478a8e3232b5a80831094927d10bbcbdd76c7bf415dbb9fb4bc6aec3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences posts mixed Q1 results",
    "summary": "Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell short. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above.  To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.",
    "url": "https://finnhub.io/api/news?id=7f64dde211c9da3d0b48b65ebbb9dae9c883ad10ed1293791a038615202648f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745529733,
      "headline": "Gilead Sciences posts mixed Q1 results",
      "id": 134067679,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead Sciences (GILD) reported first quarter earnings that topped analyst estimates, but its revenue in the quarter fell short. Yahoo Finance Senior Health Reporter Anjalee Khemlani reports the details in the video above.  To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here.",
      "url": "https://finnhub.io/api/news?id=7f64dde211c9da3d0b48b65ebbb9dae9c883ad10ed1293791a038615202648f8"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates",
    "summary": "Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=d90f5b830b2b3398ab9c704ceec84c30b0e6ab5059eaf356f68a801ccdab9ace",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745529308,
      "headline": "Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates",
      "id": 134067680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Gilead (GILD) delivered earnings and revenue surprises of -0.55% and 2.46%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=d90f5b830b2b3398ab9c704ceec84c30b0e6ab5059eaf356f68a801ccdab9ace"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates",
    "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.",
    "url": "https://finnhub.io/api/news?id=999499fafb308b4a81f32a69d33c405805aeb293e30d377eb6610a9a9b2bbb97",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745526829,
      "headline": "Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates",
      "id": 134067681,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance of $28.4 billion at the midpoint came in 1.1% below analysts’ estimates. Its non-GAAP profit of $1.81 per share was 2.1% above analysts’ consensus estimates.",
      "url": "https://finnhub.io/api/news?id=999499fafb308b4a81f32a69d33c405805aeb293e30d377eb6610a9a9b2bbb97"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.",
    "summary": "Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.",
    "url": "https://finnhub.io/api/news?id=5bbe6449314550f5d1d8c7ac130f86c76f5c3872d7f8f063095410ca0302757b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525799,
      "headline": "Gilead Dives As Its Biggest Moneymaker Misses. Here's Why It Could Still Be A 'Safe Haven' Stock.",
      "id": 134087849,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell early Friday.",
      "url": "https://finnhub.io/api/news?id=5bbe6449314550f5d1d8c7ac130f86c76f5c3872d7f8f063095410ca0302757b"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts",
    "summary": "Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.",
    "url": "https://finnhub.io/api/news?id=5266fcef00efb40ab5ac47cd78afbbbdd74c9184577ff358fd915cf1a53dd3e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525799,
      "headline": "Gilead Dives After Its Bread-And-Butter Drug Misses Sales Forecasts",
      "id": 134067682,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Two of Gilead Sciences' most important drugs missed sales expectations late Thursday. Gilead stock fell in late action.",
      "url": "https://finnhub.io/api/news?id=5266fcef00efb40ab5ac47cd78afbbbdd74c9184577ff358fd915cf1a53dd3e2"
    }
  },
  {
    "ts": null,
    "headline": "Gilead: Q1 Earnings Snapshot",
    "summary": "Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, came to $1.81 per share. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.82 per share.",
    "url": "https://finnhub.io/api/news?id=07ff2a77688f940ade53e40d82a44361bb186dae90e0a978a72bd090214d4dc3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525604,
      "headline": "Gilead: Q1 Earnings Snapshot",
      "id": 134067683,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Earnings, adjusted for costs related to mergers and acquisitions and non-recurring costs, came to $1.81 per share. The results missed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $1.82 per share.",
      "url": "https://finnhub.io/api/news?id=07ff2a77688f940ade53e40d82a44361bb186dae90e0a978a72bd090214d4dc3"
    }
  },
  {
    "ts": null,
    "headline": "Gilead posts profit, says HIV prevention drug on track for mid-June",
    "summary": "(Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales.  Adjusted earnings per share came in at $1.81, just ahead of the average analysts' estimate of $1.79, as compiled by LSEG.  Gilead's in-line product sales, slight EPS beat and lower expenses were \"positive,\" while the key catalyst for the company's shares will be a \"clean and smooth approval\" in the United States of lenacapavir for preventing HIV, said Jefferies analyst Michael Yee.",
    "url": "https://finnhub.io/api/news?id=cf9dcd4b7c11ba36a6b4b4865026f8dd1f75d74e1d91460dc9665c431cc7b7b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745525342,
      "headline": "Gilead posts profit, says HIV prevention drug on track for mid-June",
      "id": 134067684,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "(Reuters) -Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales.  Adjusted earnings per share came in at $1.81, just ahead of the average analysts' estimate of $1.79, as compiled by LSEG.  Gilead's in-line product sales, slight EPS beat and lower expenses were \"positive,\" while the key catalyst for the company's shares will be a \"clean and smooth approval\" in the United States of lenacapavir for preventing HIV, said Jefferies analyst Michael Yee.",
      "url": "https://finnhub.io/api/news?id=cf9dcd4b7c11ba36a6b4b4865026f8dd1f75d74e1d91460dc9665c431cc7b7b9"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript",
    "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ETCompany ParticipantsJacquie Ross - SVP, Treasury &amp;...",
    "url": "https://finnhub.io/api/news?id=209e9d31f708592e1f859744acdbba6d5fe0dbb41d6a3f41ef358e3d31195cff",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745524932,
      "headline": "Gilead Sciences, Inc. (GILD) Q1 2025 Earnings Call Transcript",
      "id": 134065461,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ETCompany ParticipantsJacquie Ross - SVP, Treasury &amp;...",
      "url": "https://finnhub.io/api/news?id=209e9d31f708592e1f859744acdbba6d5fe0dbb41d6a3f41ef358e3d31195cff"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Announces First Quarter 2025 Financial Results",
    "summary": "FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.",
    "url": "https://finnhub.io/api/news?id=58174175ebb38c2b97e05559f267592fa4842147e4dbe8332da972f89c4783c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745524920,
      "headline": "Gilead Sciences Announces First Quarter 2025 Financial Results",
      "id": 134067685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., April 24, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2025 results of operations.",
      "url": "https://finnhub.io/api/news?id=58174175ebb38c2b97e05559f267592fa4842147e4dbe8332da972f89c4783c7"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : First Quarter 2025 Summary of Remarks",
    "summary": "GILD Q125 Summary of Prepared Remarks ...",
    "url": "https://finnhub.io/api/news?id=5f7aceeaeecc907cae0303506228c4b40499620ef770d0527457b393a77fbb1a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745514493,
      "headline": "Gilead Sciences : First Quarter 2025 Summary of Remarks",
      "id": 134064686,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "GILD Q125 Summary of Prepared Remarks ...",
      "url": "https://finnhub.io/api/news?id=5f7aceeaeecc907cae0303506228c4b40499620ef770d0527457b393a77fbb1a"
    }
  },
  {
    "ts": null,
    "headline": "Gilead posts quarterly profit, flat revenue as cancer sales slow",
    "summary": "Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales. ...",
    "url": "https://finnhub.io/api/news?id=50306fb1e25f66710afb140d0abf9602a20f9509dc968fa5fa78f952ad025711",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745514250,
      "headline": "Gilead posts quarterly profit, flat revenue as cancer sales slow",
      "id": 134064659,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver disease, along with expense tightening, offset lower cancer drug sales. ...",
      "url": "https://finnhub.io/api/news?id=50306fb1e25f66710afb140d0abf9602a20f9509dc968fa5fa78f952ad025711"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences : First Quarter 2025 Supplementary Information",
    "summary": "CONDENSED CONSOLIDATED BALANCE SHEETS ...",
    "url": "https://finnhub.io/api/news?id=96a3648531a99f8990e3162230ee946a28ac9b39c76edda4704db8940c5eec97",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745512967,
      "headline": "Gilead Sciences : First Quarter 2025 Supplementary Information",
      "id": 134064471,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "CONDENSED CONSOLIDATED BALANCE SHEETS ...",
      "url": "https://finnhub.io/api/news?id=96a3648531a99f8990e3162230ee946a28ac9b39c76edda4704db8940c5eec97"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences, Inc. 2025 Q1 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Gilead Sciences, Inc.",
    "url": "https://finnhub.io/api/news?id=2fff34ce48e9c3711908535404d5e738146bbf399b66a5ab15c3a0467c604c28",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745511708,
      "headline": "Gilead Sciences, Inc. 2025 Q1 - Results - Earnings Call Presentation",
      "id": 134064396,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Gilead Sciences, Inc.",
      "url": "https://finnhub.io/api/news?id=2fff34ce48e9c3711908535404d5e738146bbf399b66a5ab15c3a0467c604c28"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance",
    "summary": "By Roshan Fernandez Gilead Sciences swung to a first-quarter profit, driven by higher HIV product and liver disease sales, but cut its full-year earnings guidance. The Foster City,...",
    "url": "https://finnhub.io/api/news?id=ff43d672723d0d4d3b6508ba86c232899d00b09883cad1b65e83f5bca52f8ff5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745511488,
      "headline": "Gilead Sciences Swings to 1Q Profit, But Slashes FY25 EPS Guidance",
      "id": 134064200,
      "image": "",
      "related": "GILD",
      "source": "Finnhub",
      "summary": "By Roshan Fernandez Gilead Sciences swung to a first-quarter profit, driven by higher HIV product and liver disease sales, but cut its full-year earnings guidance. The Foster City,...",
      "url": "https://finnhub.io/api/news?id=ff43d672723d0d4d3b6508ba86c232899d00b09883cad1b65e83f5bca52f8ff5"
    }
  }
]